Long-Term Outcomes and Risk Factors of Radiofrequency Ablation for T1N0M0 Papillary Thyroid Carcinoma

被引:33
作者
Li, Xinyang [1 ,2 ]
Yan, Lin [1 ]
Xiao, Jing [1 ]
Li, Yingying [1 ]
Yang, Zhen [1 ]
Zhang, Mingbo [1 ,3 ]
Luo, Yukun [1 ,2 ,3 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Ultrasound, Beijing, Peoples R China
[2] Nankai Univ, Sch Med, Tianjin, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Ultrasound, 28 Fuxing Rd, Beijing 100853, Peoples R China
基金
中国国家自然科学基金;
关键词
TASK-FORCE; CANCER; MICROCARCINOMA;
D O I
10.1001/jamasurg.2023.5202
中图分类号
R61 [外科手术学];
学科分类号
摘要
ImportanceRadiofrequency ablation (RFA) has gained increasing interest as a minimally invasive procedure to treat low-risk papillary thyroid carcinoma (PTC). Considering the indolent nature of this disease, studies in large populations with long follow-up would be invaluable to further substantiate the effectiveness of RFA.ObjectiveTo evaluate the long-term (58.5 months) outcomes of patients with T1N0M0 PTC who underwent RFA and investigate risk factors for local tumor progression (LTP).Design, Setting, and ParticipantsThis cohort study included 1613 patients aged 18 years or older with T1N0M0 PTC who underwent ultrasonography-guided RFA between January 2014 and December 2020 at the Chinese People's Liberation Army General Hospital in Beijing, China. Included in the analysis were patients with PTC (confirmed by biopsy) with a maximum diameter of 20 mm or less; no evidence of extrathyroidal extension (capsular disruption or involvement of perithyroidal tissue), lymph node metastasis, or distant metastasis on ultrasonography or computed tomography; and no evidence of an aggressive subtype of PTC on biopsy. Patients with PTC larger than 2 cm, less than 12 months of follow-up, or inadequate follow-up information were excluded. Data were analyzed in April 2023.Main Outcomes and MeasuresLong-term progression rate, disease-free survival, and complete tumor disappearance and their associations with patient and tumor characteristics. Disease-free survival was calculated using Kaplan-Meier analysis. Cox proportional hazards regression analyses were performed to assess risk factors for LTP and complete tumor disappearance.ResultsThe study comprised 1613 patients (mean [SD] age, 43.3 [10.2] years; 1256 women [77.9%]) with 1834 T1N0M0 PTC tumors. During a mean follow-up of 58.5 months (range, 27 to 111 months), LTP was observed in 69 patients (4.3%), including 42 (2.6%) with tumor recurrence and 27 (1.7%) with tumor persistence. Cumulative disease-free survival rates at 1, 3, 5, and 8 years were 98.0%, 96.7%, 96.0%, and 95.7%, respectively. The overall complication rate was 2.0% (32 patients), with 6 (0.4%) major complications. Independent risk factors for LTP included subcapsular tumor location 2 mm or less from the capsule or trachea (hazard ratio [HR], 3.36; 95% CI, 2.02-5.59; P < .001) and multifocal tumors (HR, 2.27; 95% CI, 1.30-3.96; P = .004). Furthermore, 1376 patients (85.3%) showed complete tumor disappearance at follow-up ultrasonographic examination. Factors associated with complete tumor disappearance included age 40 years or less (HR, 0.78; 95% CI, 0.70-0.87; P < .001), stage T1a tumors (HR, 0.37; 95% CI, 0.31-0.45; P < .001), and unifocal tumors (HR, 0.50; 95% CI, 0.42-0.60; P < .001).Conclusions and RelevanceIn this cohort study, ultrasonography-guided RFA for T1N0M0 PTC had excellent long-term outcomes. Patients with unifocal T1N0M0 PTC and subcapsular tumor location more than 2 mm from the capsule or trachea may be the best candidates for RFA.
引用
收藏
页码:51 / 58
页数:8
相关论文
共 29 条
[1]   Screening for Thyroid Cancer US Preventive Services Task Force Recommendation Statement [J].
Bibbins-Domingo, Kirsten ;
Grossman, David C. ;
Curry, Susan J. ;
Barry, Michael J. ;
Davidson, Karina W. ;
Doubeni, Chyke A. ;
Epling, John W., Jr. ;
Kemper, Alex R. ;
Krist, Alex H. ;
Kurth, Ann E. ;
Landefeld, C. Seth ;
Mangione, Carol M. ;
Phipps, Maureen G. ;
Silverstein, Michael ;
Simon, Melissa A. ;
Siu, Albert L. ;
Tseng, Chien-Wen .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (18) :1882-1887
[2]   Efficacy and Safety of Thermal Ablation for Treatment of Solitary T1N0M0 Papillary Thyroid Carcinoma: Multicenter Retrospective Study [J].
Cao, Xiao-Jing ;
Wang, Shu-Rong ;
Che, Ying ;
Liu, Juan ;
Cong, Zhi-Bin ;
He, Jun-Feng ;
Wang, Hong-Ling ;
Liu, Geng ;
Guo, Jian-Qin ;
Hao, Ying ;
Wang, Zhong-Hua ;
Zhou, Ying ;
Jian, Mei ;
Shi, Li-Li ;
Qi, Lu ;
Zhu, Ya-Lin ;
Wang, Xue ;
Yan, Guo-Zhen ;
Shataer, Aini ;
Liu, Xiao-Fang ;
Wei, Ying ;
Zhao, Zhen-Long ;
Peng, Li-Li ;
Li, Yan ;
Yu, Ming-An .
RADIOLOGY, 2021, 300 (01) :209-216
[3]   Five-year follow-up results of thermal ablation for low-risk papillary thyroid microcarcinomas: systematic review and meta-analysis [J].
Cho, Se Jin ;
Baek, Sun Mi ;
Na, Dong Gyu ;
Lee, Kang Dae ;
Shong, Young Kee ;
Baek, Jung Hwan .
EUROPEAN RADIOLOGY, 2021, 31 (09) :6446-6456
[4]   Long-Term Follow-Up Results of Ultrasound-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: More Than 5-Year Follow-Up for 84 Tumors [J].
Cho, Se Jin ;
Baek, Sun Mi ;
Lim, Hyun Kyung ;
Lee, Kang Dae ;
Son, Jung Min ;
Baek, Jung Hwan .
THYROID, 2020, 30 (12) :1745-1751
[5]   Active Surveillance for Small Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis [J].
Cho, Se Jin ;
Suh, Chong Hyun ;
Baek, Jung Hwan ;
Chung, Sae Rom ;
Choi, Young Jun ;
Chung, Ki-Wook ;
Shong, Young Kee ;
Lee, Jeong Hyun .
THYROID, 2019, 29 (10) :1399-1408
[6]   Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines? [J].
Cox, Caroline ;
Bosley, Maggie ;
Southerland, Lori Beth ;
Ahmadi, Sara ;
Perkins, Jennifer ;
Roman, Sanziana ;
Sosa, Julie Ann ;
Carneiro-Pla, Denise .
SURGERY, 2018, 163 (01) :75-79
[7]   2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J].
Haugen, Bryan R. ;
Alexander, Erik K. ;
Bible, Keith C. ;
Doherty, Gerard M. ;
Mandel, Susan J. ;
Nikiforov, Yuri E. ;
Pacini, Furio ;
Randolph, Gregory W. ;
Sawka, Anna M. ;
Schlumberger, Martin ;
Schuff, Kathryn G. ;
Sherman, Steven I. ;
Sosa, Julie Ann ;
Steward, David L. ;
Tuttle, R. Michael ;
Wartofsky, Leonard .
THYROID, 2016, 26 (01) :1-133
[8]   Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma A Nonrandomized Controlled Trial [J].
Ho, Allen S. ;
Kim, Sungjin ;
Zalt, Cynthia ;
Melany, Michelle L. ;
Chen, Irene E. ;
Vasquez, Joan ;
Mallen-St Clair, Jon ;
Chen, Michelle M. ;
Vasquez, Missael ;
Fan, Xuemo ;
van Deen, Welmoed K. ;
Haile, Robert W. ;
Daskivich, Timothy J. ;
Zumsteg, Zachary S. ;
Braunstein, Glenn D. ;
Sacks, Wendy L. .
JAMA ONCOLOGY, 2022, 8 (11) :1588-1596
[9]   Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under Observation [J].
Ito, Yasuhiro ;
Miyauchi, Akira ;
Kihara, Minoru ;
Higashiyama, Takuya ;
Kobayashi, Kaoru ;
Miya, Akihiro .
THYROID, 2014, 24 (01) :27-34
[10]   Long-Term Efficacy of Ultrasound-Guided Laser Ablation for Papillary Thyroid Microcarcinoma: Results of a 10-Year Retrospective Study [J].
Kim, Ho Jin ;
Chung, Seung Min ;
Kim, Hanbyul ;
Jang, Ju Young ;
Yang, Jae Hong ;
Moon, Jun Sung ;
Son, Gitak ;
Oh, Jong-Ryool ;
Bae, Jong Yup ;
Yoon, Hyundae .
THYROID, 2021, 31 (11) :1723-1729